An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Aldeyra Therapeutics to Participate in Fireside Chat at the Oppenheimer 32nd Annual Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Aldeyra Therapeutics (Nasdaq: ALDX) announced that its CEO, Todd C. Brady, will participate in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference conducted virtually from March 15-17, 2022. The discussion with analyst Justin Kim is set for 11:20 a.m. ET on March 16, 2022, and will be accessible via a webcast on Aldeyra's website, where it will remain archived for 90 days. Aldeyra focuses on therapies for immune-mediated diseases, with key products in various clinical trial phases.
Positive
None.
Negative
None.
LEXINGTON, Mass.--(BUSINESS WIRE)--
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company discovering and developing innovative therapies for the treatment of immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference. The conference is being conducted in a virtual format March 15-17, 2022.
Dr. Brady’s conversation with Justin Kim, Senior Analyst, Biotech Equity Research at Oppenheimer, is scheduled to begin at 11:20 a.m. ET Wednesday, March 16, 2022. A webcast of the presentation can be accessed on the Investors & Media section of the Aldeyra website at https://ir.aldeyra.com. Following the presentation, the webcast will be archived for 90 days.
About Aldeyra Therapeutics
Aldeyra Therapeutics discovers and develops innovative therapies designed to treat immune-mediated diseases. Our approach is to develop therapies that modulate immunological systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Two of our lead product candidates, reproxalap and ADX-629, target pre-cytokine, systems-based mediators of inflammation known as RASP (reactive aldehyde species). Reproxalap is in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. ADX-629, an orally administered RASP modulator, is in Phase 2 proof-of-concept clinical trials in psoriasis, asthma, and COVID-19. Our pipeline also includes ADX-2191 (intravitreal methotrexate 0.8%), in development for the prevention of proliferative vitreoretinopathy and the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.
